Lilly issues Complete Response Letter for Sintilimab in combination with Pemetrexed and Platinum…
The letter indicates that the review cycle is complete but the FDA is unable to approve the application in its current form,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sintilimab
Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of…
The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per…